IP Library › Patent Application 19231020

Patent Application

App. No. 19/231,020

METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 19/231,020

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.

Claims (86)

1 . A method of treating a metabolic disease or disorder in a subject in need thereof, wherein the metabolic disease or disorder is obesity, type II diabetes, diabetic retinopathy, liver fibrosis, liver cancer, or liver cirrhosis, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof:

wherein:

each R 1 is independently halogen, haloalkyl, or alkyl;

R 2 is —H, —OH, or halogen;

p is 0, 1, 2, 3, 4, or 5;

A has the structure:

wherein:

α, β, χ, and δ are each independently absent or present, and when present each is a bond;

X is C;

Z 1 is S, O, or N;

Z 2 is S, O, N, or NR 3 ;

R 3 is H, C 1 -C 4 alkyl, or oxetane; and

B is a substituted or unsubstituted fused 5-, 6-, or 7-membered ring structure.

2 . The method of claim 1 , wherein:

when α is present, then Z 1 is O or S, Z 2 is N, X is C, χ is present, and β and δ are absent;

when α is absent, then Z 1 is N, Z 2 is NR 3 , X is C, β and δ are present, and χ is absent; or

when α is absent, then Z 1 is N, Z 2 is O or S, X is C, β and δ are present, and χ is absent.

3 . The method of claim 1 , wherein A has the structure

wherein:

n is 0, 1, or 2;

α, β, χ, δ, ε, and ϕ are each independently absent or present, and when present each is a bond;

Z 1 is S, O, or N;

Z 2 is S, O, N or NR 3 ,

wherein R 3 is H, C 1 -C 4 alkyl, or oxetane;

X is C;

Y 1 , Y 2 , Y 3 and each occurrence of Y 4 are each independently CR 4 , C(R 5 ) 2 , NR 6 , O, N, SO 2 , or —(C═O)—, wherein:

R 4 is H, halogen, C 1 -C 10 alkyl, C 1 -C 10 cycloalkyl, —(C 1 -C 10 alkyl), —C(O)OH, —C(O)O(C 1 -C 10 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —NHC(O)NH(C 1 -C 10 alkyl), —NHC(O)N(C 1 -C 4 alkyl) 2 , —SO 2 NH(C 1 -C 10 alkyl), —SO 2 N(C 1 -C 10 alkyl) 2 , —CN, or —CF 3 ;

R 5 is H or C 1 -C 10 alkyl; and

R 6 is H, C 1 -C 10 alkyl, C 3 -C 6 cycloalkyl, —(C 1 -C 10 alkylene)CF 3 , —(C 1 -C 10 alkylene)OCH 3 , —(C 1 -C 10 alkylene)-halogen, —SO 2 (C 1 -C 10 alkyl), —SO 2 (C 1 -C 10 alkylene)-CF 3 , —SO 2 (C 1 -C 10 alkylene)OCH 3 , —SO 2 (C 1 -C 10 alkylene)-halogen, —C(O)(C 1 -C 10 alkyl), —C(O)(C 1 -C 10 alkylene)CF 3 , —C(O)(C 1 -C 10 alkylene)OCH 3 , —C(O)(C 1 -C 10 alkylene)-halogen, —C(O)NH(C 1 -C 10 alkyl), —C(O)N(C 1 -C 10 alkyl) 2 , —(C 1 -C 10 alkyl)C(O)OH, —C(O)NH 2 , or oxetane.

4 . The method of claim 1 , wherein:

when α is present, then Z 1 is O or S, Z 2 is N, X is C, χ is present, and β and δ are absent;

when α is absent, then Z 1 is N, Z 2 is N, X is C, β and δ are present, and χ is absent; or

when α is absent, then Z 1 is N, Z 2 is O or S, X is C, β and δ are present, and χ is absent; and

when ε and ϕ are each present, then n=1, and each of Y 1 , Y 2 , Y 3 , and Y 4 , are independently —CR 4 — or N; or

when ε and ϕ are each absent, then n=0, 1 or 2, each of Y 1 , Y 2 , Y 3 , and each occurrence of Y 4 are independently C(R 5 ) 2 , NR 6 , O, or SO 2 .

5 . The method of claim 1 , wherein:

β and δ are present;

α, χ, ε, and ϕ are absent;

Z 1 is N;

Z 2 is O, S, or NR 3 ;

R 3 is H, C 1 -C 4 alkyl, or oxetane; and

X is C.

6 . The method of claim 1 , wherein A has the structure

wherein:

n is 0;

R 3 is H, C 1 -C 4 alkyl, or oxetane;

Y 1 and Y 3 are each CH 2 or C(CH 3 ) 2 ;

Y 2 is O, SO 2 , or NR 6 ; and

R 6 is H, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, —(C 1 -C 4 alkylene)CF 3 , —(C 1 -C 4 alkylene)OCH 3 , —(C 1 -C 4 alkylene)-halogen, —SO 2 (C 1 -C 4 alkyl), —SO 2 (C 1 -C 4 alkylene)CF 3 , —SO 2 (C 1 -C 4 alkylene)OCH 3 , —SO 2 (C 1 -C 4 alkylene)-halogen, —C(O)(C 1 -C 4 alkyl), —C(O)(C 1 -C 4 alkylene)CF 3 , —C(O)(C 1 -C 4 alkylene)OCH 3 , —C(O)(C 1 -C 4 alkylene)-halogen, —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —(C 1 -C 4 alkylene)C(O)OH, —C(O)NH 2 , or oxetane.

7 . The method of claim 6 , wherein:

n is 1;

R 3 is H, C 1 -C 4 alkyl, or oxetane;

Y 1 and Y 4 are CH 2 or C(CH 3 ) 2 ;

Y 2 and Y 3 are each CH 2 or C(CH 3 ) 2 , O, SO 2 , or NR 6 ; and

8 . The method of claim 6 , wherein:

n is 2;

R 3 is H, C 1 -C 4 alkyl, or oxetane;

Y 1 and Y 4 are CH 2 or C(CH 3 ) 2 ;

Y 2 and Y 3 are each CH 2 or C(CH 3 ) 2 , O, SO 2 , or NR 6 ; and

9 . The method of claim 6 , wherein A has the structure:

10 . The method of claim 9 , wherein:

R 6 is C(O)CH 3 , C(O)CH 2 CH 3 , —C(O)CH 2 CH 2 CH 3 , —C(O)CH(CH 3 ) 2 , —C(O)CH 2 CH(CH 3 ) 2 , —C(O)t-Bu, —C(O)CH 2 OCH 3 , —C(O)CH 2 CF 3 , —C(O)CH 2 Cl, —C(O)CH 2 F, —C(O)CH 2 CH 2 OCH 3 , —C(O)CH 2 CH 2 CF 3 , —C(O)CH 2 CH 2 Cl, —C(O)CH 2 CH 2 F,

11 . The method of claim 4 , wherein A has the structure

wherein:

Y 1 , Y 2 , Y 3 and each occurrence of Y 4 are each independently CR 4 , or N;

wherein:

R 3 is H, halogen, C 1 -C 10 alkyl, C 1 -C 10 cycloalkyl, —O(C 1 -C 10 alkyl), —C(O)OH, —C(O)O(C 1 -C 10 alkyl), —C(O)NH 2 , —C(O)NH(C 1 -C 4 alkyl), —C(O)N(C 1 -C 4 alkyl) 2 , —NHC(O)NH(C 1 -C 10 alkyl), —NHC(O)N(C 1 -C 4 alkyl) 2 , —SO 2 NH(C 1 -C 10 alkyl), —SO 2 N(C 1 -C 10 alkyl) 2 , —CN, or —CF 3 .

12 . The method of claim 16 , wherein

Y 1 , Y 2 , Y 3 and Y 4 are CH;

Y 1 , Y 2 , Y 3 are CH and Y 4 is N;

Y 1 , Y 2 , Y 4 are CH and Y 3 is N;

Y 1 , Y 3 , Y 4 are CH and Y 2 is N; or

Y 2 , Y 3 , Y 4 are CH and Y 1 is N.

13 . The method of claim 16 , wherein A has the structure

wherein:

R 4 is H, halogen, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, —O(C 1 -C 4 alkyl), —CN, —CF 3 , —C(O)OH, —C(O)NH 2 , —C(O)N(CH 3 ) 2 , —C(O)NHCH 3 , or —NHC(O)N(CH 3 ) 2 .

14 . The method of claim 1 , wherein each R 1 is independently F, Br, Cl, C 1-6 haloalkyl, or C 1-6 alkyl.

15 . The method of claim 1 , wherein each R 1 is independently F or CF 3 .

16 . The method of claim 1 , wherein 24 hours after administration of a compound of Formula (I), a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof, the serum or plasma levels of RBP4 are reduced by at least 50% from baseline.

17 . The method of any claim 1 , wherein 24 hours after administration of a compound of Formula (I), a pharmaceutically acceptable salt, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof, the serum or plasma levels of RBP4 are reduced by at least 1 mg/dL.

18 . The method of claim 1 , wherein the disease or disorder is obesity.

19 . The method of claim 1 , wherein the disease or disorder is non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR).

20 . The method of claim 1 , wherein the disease or disorder is liver fibrosis, liver cirrhosis, or liver cancer.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2025

From: LIN, YU-HSIN TOM; WANG, CHENG-CHI IRENE

To: BELITE BIO, INC

Reel/Frame 073031/0811 →